GERN

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Geron (GERN) has drawn fresh attention after issuing 2026 earnings guidance tied to RYTELO net product revenue and releasing second quarter and half year 2026 results on 5 August, including updated revenue and net loss figures. See our latest analysis for Geron. Geron’s latest guidance and earnings update landed alongside a share price of $1.48, with a 7 day share price return of 14.73% and a 1 year total shareholder return of 15.62%. The 3 year total shareholder return is down 50.99%, which points to some improving momentum in the short term against a still weak longer term record. If you are reassessing your biotech exposure after Geron’s update, this can be a good moment to scan the broader healthcare AI opportunity set through the 43 healthcare AI stocks. Bulls point to Geron’s growing RYTELO revenue and narrower recent losses. Bears focus on the ongoing losses and long 3 year drawdown. The key question is which side the current valuation really supports as you look at the stock today. On the latest figures, the most followed Geron narrative pegs fair value at $3.40 compared with a last close of $1.48. This frames the stock as heavily discounted and puts a spotlight on the growth and profitability expectations sitting behind that gap. Read the complete narrative. If you want to understand why this narrative still points to a fair value more than double Geron’s share price, the real story sits in the projected shift from losses to profitability, the pace of expected revenue expansion, and the earnings multiple that needs to hold for that valuation to make sense. The numbers behind those assumptions are where the debate really starts. Result: Fair Value of $3.40 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Geron’s reliance on a single drug and the potential need for further equity financing still remain in the background as real tests of this undervalued story. Find out about the key risks to this Geron narrative. With sentiment on Geron split between optimism and caution, this is a moment to check the data yourself and move quickly while views are still forming. To see why some investors are focusing on potential upsides, take a closer look at the 4 key rewards. If Geron has you reassessing your next move, do not stop here. Your next strong idea could be sitting just outside your current watchlist. Target potential deep value opportunities by scanning companies flagged in the 52 high quality undervalued stocks. Strengthen the foundation of your portfolio by reviewing stocks in the solid balance sheet and fundamentals stocks screener (48 results). Hunt for overlooked opportunities with quality metrics to back them up through the screener containing 21 high quality undiscovered gems. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include GERN. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Image source: The Motley Fool. Wednesday, Aug. 5, 2026 at 8:00 a.m. ET SVP, Investor Relations and Corporate Affairs - Dawn Schottlandt Chief Executive Officer - Harout Semerjian Chief Commercial Officer - Ahmed ElNawawi Executive Vice President of Research and Development and Chief Medical Officer - Joseph Eid Chief Financial Officer - Michelle Robertson Need a quote from a Motley Fool analyst? Email [email protected] Operator: Hello, and welcome to the Geron Corporation Second Quarter 2026 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the call over to Dawn Schottlandt, SVP, Investor Relations and Corporate Affairs. Dawn Schottlandt: Good morning, everyone. Welcome to the Geron Corporation Second Quarter 2026 Earnings Conference Call. Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations and other projections, including those related to our 2026 financial guidance, our current RYTELO commercialization strategy and related opportunities in the U.S. and the EU, the therapeutic potential of RYTELO, other anticipated clinical and commercial events and related timelines, the sufficiency of our financial resources and other statements that are not historical facts, which, of course, involve risks and uncertainties that could cause actual events, performance and results to differ materially from those contained in these forward-looking statements. Therefore, I refer you to the risks and uncertainties described in today's earnings release and under the heading Risk Factors in Geron's most recent periodic reports filed with the SEC, which identify important factors that could cause actual results to differ materially from those contained in these forward-looking statements and future updates to Geron's risks and uncertainties disclosures, including in its upcoming quarterly report on Form 10-Q. Geron undertakes no duty or obligation to update its forward-looking statements. Joining me on today's call are several members of Geron's management team: Harout Semerjian, Chief Executive Officer; Ahmed ElNawawi, our Chief Commercial Officer; Dr. Joseph Eid, Executive Vice President of Research and Development and Chief Medical Officer; and Michelle Robertson, our Chief Financial Officer. With that, I'll turn the call over to Harout to discuss Geron's progress and strategy. Harout Semerjian: Thank you, Dawn, and good morning, everyone. Our second quarter results demonstrate the continued progress we are making and the momentum we are building as we execute our strategy outlined at the beginning of the year. We delivered another quarter of net revenue growth, expanding RYTELO's reach to more eligible patients, strengthened the clinical evidence supporting RYTELO, continued investing in future growth opportunities, all while remaining financially disciplined. Let me start with our commercial performance. Second quarter net revenue increased 17% year-over-year and 11% quarter-over-quarter to $57.5 million. Through the first half of 2026, net revenue grew by approximately 24% compared to the same period a year ago, demonstrating sales momentum as our refocused commercial strategy gains traction. During the quarter, we continued to expand awareness and education among healthcare professionals with a focus on identifying appropriate second-line patients. At EHA, we presented the first real-world evidence study of RYTELO in lower-risk MDS with findings that were generally consistent with results from our Phase III IMerge trial and further validated RYTELO's profile in a broader patient population. As for operating expenses, we continue to make prudent investment decisions while delivering top line growth. In the first half of 2026, our total operating expenses decreased by 4% compared to the same period a year ago, while net revenue increased 24%. With $327 million of cash on hand at the end of quarter 2, our balance sheet is strong and provides us with the flexibility to continue investing in our commercial business, advance our science and evaluate opportunistic innovation. As part of that strategy, we recently welcomed Chinmaya Rath as our Chief Business Officer. Chinmaya brings deep business development experience and a proven track record of identifying and executing strategic growth opportunities. His appointment reflects our commitment to maximizing the value of our current portfolio and building a leading hematology company. Beyond our U.S. focus, we recognize the significant unmet need for patients with low-risk MDS in Europe and beyond and are exploring gated commercial strategies to bring RYTELO to appropriate patients while maintaining pricing integrity in the U.S. We expect to share our European commercialization plans before year-end as previously stated. Turning to our Phase III IMpactMF trial in relapsed/refractory myelofibrosis. Over the first half of 2026, we have proactively engaged with regulatory authorities and external experts to ensure the interim analysis design is adequate to support registration should the DMC recommend unblinding for positive efficacy. As such, we are evaluating a modification to the event threshold for the interim analysis. At this time, our projected timelines remain unchanged. We will communicate any changes to these projections as appropriate. As we look to the second half of the year, we remain focused on executing across each of our strategic priorities, including growing RYTELO demand. Based on our solid net revenue performance in the first half of the year, we anticipate coming in at the mid- to high end of our full year 2026 RYTELO net product revenue guidance range of $220 million to $240 million. We continue to expect total operating expenses for 2026 in the range of $230 million to $240 million. We're confident in our team, strategy and operating model and encouraged by the momentum we have generated through the first half of the year. Most importantly, we're committed to reaching more eligible patients with low-risk MDS and making a meaningful difference in their lives. With that, I'll turn it over to ElNawawi to provide more detail on RYTELO's commercial performance and our execution. Ahmed ElNawawi: Thank you, Harout. We delivered solid RYTELO net revenue growth in the second quarter, marking our third straight quarter of demand growth and continue to execute on our commercial strategy to build sustainable growth and long-term value. In the second quarter, we achieved 5% demand growth for RYTELO compared to the first quarter of this year and an 8% increase in prescribing accounts, expanding our footprint to approximately 1,575 accounts since launch. First and second-line patient starts on a rolling 12-month basis was 34%. These results reflect the steady execution of our refocused commercial strategy. As awareness continues to grow, more appropriate RYTELO patients are being identified earlier in their treatment journey. We believe the second-line lower-risk MDS setting represents a significant opportunity to bring RYTELO to more patients, where we estimate there to be around 8,000 eligible patients in the U.S. Our commercial strategy remains focused on initiatives that we believe will drive long-term adoption of RYTELO. We are prioritizing high-volume community treatment centers, identifying appropriate patients earlier in their treatment journey, strengthening account management and using targeted omnichannel engagement to deliver consistent evidence-based messaging across healthcare professionals preferred channels. These efforts continue to increase awareness, build HCP confidence in RYTELO and support its positioning as the standard of care in the second-line setting. In addition to our strategy, strong fundamentals, including RYTELO's broad label, NCCN treatment guidelines, growing real-world evidence and data from the IMerge trial provide a solid foundation for continued adoption in low-risk MDS. As physicians' experience and awareness continue to build, we believe we are well positioned to accelerate demand growth and bring RYTELO to more eligible lower-risk MDS patients. I now turn it over to Joe to discuss our medical and scientific engagement efforts. Joseph Eid: Thanks, ElNawawi. Scientific engagement and evidence generation remains central to how we support HCPs caring for patients with lower-risk MDS. Building on the data presented at ASH 2025, anecdotally, we're seeing a consistent increase in awareness of RYTELO and a meaningful scientific dialogue as physicians continue to incorporate emerging data into clinical practice. There's good understanding of the findings suggesting that treatment-emergent cytopenias are consistent with on-target activity and what those insights may mean for patient management within the approved indication. We're also seeing increased interest from leading academic centers in collaborating through investigator-sponsored studies and real-world evidence initiatives. During the second quarter, this continued dialogue was evident at both ASCO and EHA, where we had the opportunity to share new data and engage directly with the global hematology community. We were encouraged by the level of interest and the quality of discussions, which reflected growing engagement with RYTELO and our broader investigator-sponsored efforts. At EHA, we presented the first real-world evidence study evaluating RYTELO in patients with lower-risk MDS. The investigator-sponsored study conducted in collaboration with Moffitt Cancer Center is a 2-part retrospective and prospective study designed to evaluate the safety and clinical efficacy of RYTELO in advanced heavily transfusion-dependent patients with lower-risk MDS, including patients with extensive prior therapies and after luspatercept failure. The data highlighted at EHA was from the retrospective portion of the study. The findings were encouraging and generally consistent with the Phase III IMerge trial, reinforcing the safety, efficacy and tolerability profile of RYTELO in a broader real-world patient population. The data also showed a trend toward optimal management of cytopenias and improved responses when RYTELO was used within the first 3 lines of therapy. Real-world evidence is an important complement to clinical trial data, helping us better understand how therapies perform in routine clinical practice. These findings add to the growing body of evidence for supporting the use of RYTELO as a preferred second-line treatment option following prior therapy for lower-risk MDS and significant transfusion burden. We expect the prospective portion to provide additional insights, which we look forward to sharing at a future scientific meeting. Beyond our efforts in lower-risk MDS, additional presentations at ASCO and EHA highlighted progress across our myelofibrosis program, including an updated overall survival analysis from the Phase II IMbark trial compared with real-world data. These findings, together with the totality of evidence generated across our clinical program, continue to support the potential of imetelstat in myelofibrosis and reinforce our confidence in overall survival as the appropriate endpoint for our Phase III IMpactMF trial. It is critical to maintain ongoing dialogue with regulatory authorities when conducting registrational trial. And as IMpactMF approaches the 1-year anniversary of enrollment completion, we have proactively engaged with the regulatory authorities over the first half of 2026 to ensure the interim analysis can support registration if the DMC recommends unblinding the trial for positive efficacy. As such, we are evaluating a modification to the event threshold for the interim analysis to ensure an appropriate evaluation of imetelstat's benefit risk profile while we remain blinded to the treatment assignment. At this time, our projected timelines remain unchanged. Our base case remains progression to the final overall survival analysis in the second half of 2028, while an earlier positive outcome at the interim analysis would represent an upside scenario. We will communicate any changes to these projections as appropriate. As a final note, the upcoming fall Congress season, including SOHO and ASH, will provide additional opportunities to share data, engage with the hematology community and continue building on the scientific momentum we've established this year. I'll now hand it over to Michelle to walk through the financials. Michelle Robertson: Thank you, Joe, and good morning, everyone. For more detailed results from the second quarter, please refer to the press release we issued this morning, which is available on our website. Our first half financial results, including 24% net revenue growth compared to the same period in 2025, along with a 4% decrease in total operating expenses compared to the same period in 2025, underscore the progress we are making on our operational execution while maintaining financial discipline. We are in a strong financial position and have the resources to deliver on our 2026 financial guidance while advancing the strategic priorities that will drive durable value creation for both patients and our shareholders. In the second quarter, total net revenue for the 3 months ended June 30, 2026, was $57.5 million compared to $49 million in Q2 2025. Gross to net deductions increased to 20.7% for the 3 months ended June 30, 2026, compared to 15.3% for the same period in 2025. For the remainder of 2026, we continue to expect gross to net to be in the low to mid-20s. Research and development expenses for the 3 months ended June 30, 2026, were $22 million compared to $21.7 million in expenses for the same period in 2025. The increase in research and development expenses was a result of investments in CMC and was partially offset by lower headcount costs from the workforce reduction in December of 2025. For 2026, we expect continued investment in CMC and in our clinical development programs with lower employee costs driven by the decrease in headcount as a result of the workforce reduction in 2025. Selling, general and administrative expenses for the 3 months ended June 30, 2026, were $38.9 million compared to $38.6 million for the same period in 2025. This change was primarily due to higher marketing expenses, partially offset by lower general and administrative personnel-related expenses as a result of the workforce reduction in December 2025. For 2026, we expect continued investment in our RYTELO commercialization strategy and flat G&A spend. Total operating expenses, excluding cost of goods sold for the 3 months ended June 30, 2026, were $60.7 million compared to $60.3 million for the same period in 2025. Continued investments in commercial strategy and CMC were partially offset by lower headcount costs from the workforce reduction in December 2025. As of June 30, 2026, we had approximately $327 million in cash, cash equivalents, restricted cash and marketable securities compared to $341 million as of March 31, 2026. We are committed to maintaining our financial discipline and are well positioned to fund growth from our current operations. Based on our solid performance and execution to date, we expect to come in at the mid- to high end of our 2026 RYTELO net revenue guidance of $220 million to $240 million, reflecting consistent quarter-over-quarter net revenue growth throughout the year. Our total operating expense guidance of $230 million to $240 million reflects investment to accelerate RYTELO growth while maintaining operating expense discipline. We are well capitalized and on track to deliver on our strategic and financial priorities for the year. With that, I'll turn the call back to Harout for closing remarks. Harout Semerjian: Thanks, Michelle. As you've heard today, we've made meaningful progress through the first half of the year in advancing the strategy we outlined at the beginning of 2026. With a patient-focused and performance-driven Geron team, we are poised to deliver strong commercial execution, continued scientific engagement and disciplined financial management. We're entering the second half of 2026 with confidence in our strategy, our team and the opportunities ahead. The focus is on expanding RYTELO's reach to more eligible patients in the U.S., expanding access to RYTELO in other geographies, advancing our Phase III IMpactMF program and evaluating opportunistic innovation that supports our long-term vision of building Geron into a leading hematology company. Operator, we're now ready to start the Q&A session. Operator: [Operator Instructions] And our first question comes from Tara Bancroft of TD Cowen. Tara Bancroft: It's a great quarter. Really happy to see it. So I guess my question is going forward, looking back on last year, it looked like seasonality, it did coincide with some major changes that you guys had at the company that you mentioned. So I'm curious if you have any thoughts on how seasonality may impact the rest of this year, but potentially be offset by these efforts that you've guided to inflecting in the back half of the year? Harout Semerjian: Thank you, Tara, and good to hear from you. Yes, we are very excited about this quarter, obviously, $57.5 million of net revenue sales, 17% growth year-over-year, 11% growth quarter-over-quarter is something that as a team, we're very happy about. Of course, seasonality and other things have played a role, but we really don't see that. Our finance teams and commercial teams have been very disciplined in terms of how we can anticipate some of these things. But maybe, Michelle, if you want to tackle some of that question, that would be great. Michelle Robertson: Yes. I mean, Tara, we continue to manage our inventory within our range of 2 to 4 weeks. And as I've guided that we're very comfortable with the gross to net projection in low to mid-20s. So we don't expect significant spikes or decreases in the back half of the year. As Harout mentioned, we're looking for consistent growth quarter-over-quarter, and we expect to be on the higher end of our revenue guidance. Operator: And our next question comes from Emily Bodnar of H.C. Wainwright. Emily Bodnar: Congrats on the quarter as well. Maybe as you're kind of growing your ordering accounts for RYTELO, are you seeing increased reordering from existing accounts? Or is growth kind of mainly coming from the new accounts? And then secondly, as you're kind of seeing more of an increase into first-line, second-line patients compared to third-line patients, are you also seeing an increase in persistence and time on therapy with that as well? Harout Semerjian: Yes. Thank you, Emily. I'll open it up, and then I'll hand it to ElNawawi for additional color. Our growth is really coming from both. One of the things which we're quite happy about is our growth is now predominantly driven by the community accounts. which is really where the further growth will happen and the further penetration would happen. But ElNawawi, do you want to give some additional color on that? Ahmed ElNawawi: Yes. Thank you, Emily, for the question. The growth is coming from both, as Harout mentioned. We do expect as our strategy continues to be executed successfully that the breadth will be playing a smaller component in the second half of the year and the depth is becoming a more focused metric that we are focused on. And it was very encouraging to see that the community accounts, especially the high-tier community accounts are responding well to our messages, and that is playing a bigger role in our book of business. Duration of therapy is something that we don't have a good metric to track. We don't see it either going up or down because we don't really have a decent denominator, if you will, that allows us to measure that. Operator: [Operator Instructions] And our next question comes from Stephen Willey of Stifel. Stephen Willey: Congrats on the progress. So it sounds like you are in discussion with FDA around potentially modifying the event threshold for the interim. Just curious if there's been any contemplation of altering the threshold for the final OS analysis as well. Harout Semerjian: Thanks, Steve, and thanks for the question. Maybe a couple of words from me before turning it to Joe. We've always maintained that our -- from our planning purposes, we think that these trials, which are overall survival primary endpoint need time to mature. That's why our base planning is always for it to go to full length. With the caveat that there is an interim analysis that is built into the trial design, which is very appropriate in our opinion. And we want to make sure that those interims are very well and consistent with the regulators, given that these trials have taken many, many years to be fully enrolled. So that's why we are having those conversations on the interim. It doesn't change the design of the trial, but that's one where we're engaging with the regulators at this point predominantly around the interim rather than the full design of the trial. We do believe the trial is a very appropriate trial for a patient population and for what we're trying to show over here. Joe, anything else you want to add? Joseph Eid: Yes. I mean we're making sure that there's alignment on the interim analysis, whether it's the threshold given that the trial started in the early 2020s and FDA changes, standard of care changes. So that's appropriate. As far as the final analysis, the OS primary endpoint as well as the timing are not changing. Operator: [Operator Instructions] And our next question comes from Gil Blum of Needham. Unknown Analyst: Congrats on the quarter. This is Jonathan on for Gil. Just a quick question here around the EU commercial strategy. I know you guys mentioned that you guys are thinking about pricing dynamics, obviously, as you think about a potential EU strategy. I just wanted to clarify that with MFN concerns, this would mean countries that don't have visible net prices. Also, just wanted to see if potential paths forward continue -- or sorry, potential paths forward include potential partnerships? Harout Semerjian: Thank you, Jonathan, for the question -- for the 2 questions. Yes. Look, I mean, our vision is to have RYTELO help as many patients as possible in the U.S. and ex-U.S. As we have mentioned before, we believe there is as much opportunity in terms of patient numbers in Europe as there is in the U.S., and that is in the thousands. So that is something which we want to actively pursue and see what are the optimal ways of helping those patients. As you know, predominantly, our trials have actually been conducted in Europe. So there's a lot of advocacy, a lot of medical experts who have hands-on experience in Europe, and we're engaging with them. We're engaging with the payers as well. We understand the MFN dynamic, and that's something we're monitoring it very closely. The MFN itself is actually evolving as well. We're waiting for more updates on the Globe and Guard models. And once we have those, we'll have a more further look into that. But the fact remains that there are thousands of patients who can really help. And that's why we've said we want to actively pursue a strategy in Europe. And it can include or exclude partnership conversations as well, Jonathan. I think in the world of MFN, everybody is learning how to launch therapies and bring it to more patients outside. So we believe that this is one where given that the rules are evolving, we believe that we can have those conversations and come up with an update to the market back before end of the year, as we have previously mentioned, on what would be an optimized strategy ex-U.S., in particular, Europe, in particular, some of the major countries like Germany and France. Does that answer your question? Unknown Analyst: Yes, appreciate it. Thank you. Operator: I show no further questions at this time. I'd like to turn it back to Harout Semerjian for closing remarks. Harout Semerjian: Thank you, everyone, for joining our call today. We look forward to updating you on our progress in the next quarters, and I'm sure we're going to have a lot of one-on-ones as well. So looking forward to that. Thank you. Operator: This concludes today's conference call. Thank you for participating, and you may now disconnect. Before you buy stock in Geron, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Geron wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $396,758!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,300,820!* That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of August 6, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Geron (GERN) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

Achieved $57.5 million in RYTELO® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended Q2 2026 with cash, cash equivalents, restricted cash and marketable securities of $327 million Broadened leadership team with the appointment of Chinmaya Rath as Chief Business Officer Company to host conference call and webcast today, August 5, 2026, at 8:00 a.m. ET FOSTER CITY, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the second quarter of 2026 and recent business highlights. “We are executing a focused strategy to build a leading hematology company, which starts with bringing RYTELO to more eligible patients impacted by LR-MDS in the U.S. Our team delivered a third consecutive quarter of RYTELO demand growth, and in the first half of 2026, grew net revenue by 24% while decreasing total operating expenses by 4% compared to the same period last year,” said Harout Semerjian, President and Chief Executive Officer of Geron. “With an estimated 8,000 second-line LR-MDS patients in the U.S., we see a meaningful opportunity to continue growing demand for RYTELO in 2026 and beyond. We also have the opportunity to create additional long-term value by expanding access to RYTELO in other geographies, advancing our Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis and pursuing strategic innovation to develop and commercialize new therapies for people living with blood cancers.” Recent Business Highlights Reported RYTELO net product revenue of $57.5 million in the second quarter of 2026. Presented the first real-world evidence study of RYTELO in patients with lower-risk myelodysplastic syndromes (LR-MDS) at the European Hematology Association (EHA) 2026 Congress. The retrospective portion of the investigator-sponsored study, conducted at the Moffitt Cancer Center, reported safety and clinical efficacy of imetelstat in advanced, heavily transfusion-dependent patients with LR-MDS, including patients with extensive prior therapies and after luspatercept failure. The efficacy, safety and tolerability observed were generally consistent with findings from the Phase 3 IMerge trial in a broader patient population.1 Presented two abstracts studying imetelstat in relapsed/refractory myelofibrosis at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including an updated overall survival analysis from the Phase 2 IMbark trial compared with real-world data. Broadened the leadership team with the appointment of Chinmaya Rath as Chief Business Officer. Second Quarter 2026 Financial Results Cash and Marketable Securities As of June 30, 2026, Geron had approximately $326.9 million in cash, cash equivalents, restricted cash and marketable securities, compared to $341.0 million as of March 31, 2026, which provides the Company with cash for the foreseeable future. Net Loss For the three months ended June 30, 2026, the Company reported a net loss of $16.7 million, or $0.02 per share, compared to $16.4 million, or $0.02 per share, for the three months ended June 30, 2025. The increase in net loss is directly attributable to non-cash inventory-related expenses, which were partially offset by an increase in RYTELO net product revenue for the quarter. Revenues Total product revenue, net for the three months ended June 30, 2026, was $57.5 million, compared to $49.0 million for the three months ended June 30, 2025. Costs and Operating Expenses Total costs and operating expenses for the three months ended June 30, 2026, were $70.0 million, compared to $61.5 million for the three months ended June 30, 2025. The increase is primarily due to non-cash inventory-related expenses. Cost of goods sold was approximately $9.2 million for the three months ended June 30, 2026, compared to $1.2 million for the three months ended June 30, 2025, which consisted of costs to manufacture and distribute RYTELO. The increase is primarily due to non-cash inventory-related expenses.        Research and development expenses for the three months ended June 30, 2026, were $22.0 million, compared to $21.7 million for the same period in 2025. The increase in research and development expenses was a result of investments in manufacturing and was partially offset by lower headcount costs from the workforce reduction in December 2025. Selling, general and administrative expenses for the three months ended June 30, 2026, were $38.9 million, compared to $38.6 million for the same period in 2025. We continue to invest in our RYTELO commercialization strategy while managing lower general and administrative expenses primarily due to a decrease in personnel expense as a result of the workforce reduction in December 2025. 2026 Financial Guidance For fiscal year 2026, the Company expects RYTELO net product revenue to be in the range of $220 million to $240 million. Geron also expects total operating expenses to be between $230 million and $240 million. Total operating expenses include non-cash items such as stock-based compensation expense, amortization of debt discounts and issuance costs, inventory write-offs, depreciation and amortization. Based on current operating plans and assumptions, the Company believes that its existing cash, cash equivalents, restricted cash and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future. Conference Call Geron will host a conference call at 8:00 a.m. ET on Wednesday, August 5, 2026, to discuss business updates and second quarter 2026 financial results. A live webcast of the conference call will be available on the “Investors & Media” page of the Company’s website at www.geron.com. A replay of the webcast will be archived and available on the Company's website. 1. Data presented at the European Hematology Association (EHA) 2026 Congress: Komrokji RS, et al. “Real-world Outcomes of Imetelstat: Interrogating Safety, Efficacy and Predictors of Response in Heavily Pretreated Lower-Risk MDS Patients.” Poster PF670. June 11-14, 2026, Stockholm, Sweden. About RYTELO (imetelstat)RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor approved in the U.S. for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks. In addition, RYTELO is approved in the European Union as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission. Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at https://pi.geron.com/products/US/pi/rytelo_pi.pdf. About GeronGeron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. To learn more, visit www.geron.com or follow us on LinkedIn. Use of Forward-Looking StatementsExcept for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) Geron’s 2026 financial guidance, including its expected full year 2026 RYTELO net product revenue range and total operating expense range; (ii) Geron being positioned to build in the future on RYTELO demand and net revenue growth in the second half of 2026; (iii) Geron’s potential European lower-risk MDS commercial strategy for RYTELO; (iv) Geron’s 2026 priorities, including remaining focused on growing RYTELO net revenue in the U.S., pursuing pathways to bring RYTELO to patients outside of the U.S., advancing its Phase 3 IMpactMF trial, remaining financially disciplined, and evaluating opportunistic innovation; (v) the expected timing of initial data from investigator-sponsored and real-world evidence trials focusing on RYTELO’s mechanistic studies, combinations and sequencing, earlier-line use and new settings; (vi) the pooled analysis from the IMerge population that suggests treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in LR-MDS; (vii) Geron’s belief that its existing cash, cash equivalents, restricted cash and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future; and (viii) and other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether Geron is successful in commercializing RYTELO for the treatment of certain patients with lower-risk MDS with transfusion dependent anemia and achieves market acceptance across the breadth of the eligible patient segments in RYTELO’s approved indication; (b) whether the FDA, European Commission and other regulatory authorities will approve imetelstat for other indications with labeling claims that are necessary or desirable for the successful commercialization of RYTELO and without significant labeling restrictions or requirements in an approved label; (c) Geron’s plans to commercialize RYTELO outside of the U.S., including Geron’s lack of experience selling, marketing and commercializing an approved drug outside of the U.S., and risks related to pricing, reimbursement, distribution, supply chain and other operational requirements of operating outside of the U.S.; (d) Geron’s future opportunities and plans, including the uncertainty of future revenues, expenses and other financial performance and results, and the related risk that Geron may be unable to meet its 2026 financial guidance; (e) whether Geron overcomes potential delays and other adverse impacts that may be caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing, supply chain, pricing, coverage and reimbursement, market penetration, regulatory, healthcare or geopolitical challenges in order to obtain and maintain the financial resources for and meet expected timelines and planned milestones; (f) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (g) whether any future safety or efficacy results of RYTELO treatment cause its benefit-risk profile to become unacceptable or negatively impact commercialization, regulatory approvals or clinical development; (h) whether imetelstat actually demonstrates disease-modifying activity in patients, including transfusion independence in LR-MDS, and the ability to target the malignant stem and progenitor cells of the underlying disease; (i) whether Geron meets its post-marketing requirements and commitments for RYTELO; (j) whether there are failures or delays in manufacturing or supplying sufficient quantities of RYTELO (imetelstat) or other clinical trial materials that negatively impact commercialization of RYTELO or the conduct and timing of clinical trials; (k) that the expected timing for initial data from investigator-sponsored and real-world evidence trials may be delayed, perhaps significantly; (l) that the projected timing for the interim and final analyses of the Phase 3 IMpactMF trial may prove to be incorrect and may be delayed, perhaps significantly, depending on actual death rates in the trial which are beyond Geron’s control; (m) whether Geron stays in compliance with and satisfies its obligations under its debt and synthetic royalty financing agreements; (n) whether Geron successfully manages the changes in its workforce and realizes expected operating expense savings and business efficiencies resulting from its completed strategic restructuring plan; and (o) as it relates to Geron’s belief as to the sufficiency of its cash resources, if Geron does not generate net revenues from commercial sales of RYTELO at the levels it anticipates, if it experiences unforeseen events or chooses to make other investments in its business, or if its assumptions regarding its projected operating expenses are otherwise incorrect, Geron may require additional funding, which may not be available to Geron on commercially-reasonable terms or at all. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere in such filings and reports, including Geron’s annual report on Form 10-K for the year ended December 31, 2025, Geron’s quarterly report on Form 10-Q for the quarter ended March 31, 2026, and Geron’s upcoming quarterly report on Form 10-Q for the quarter ended June 30, 2026, and subsequent filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances. Note 1: Derived from audited financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2025. Investors and MediaDawn SchottlandtSenior Vice President, Investor Relations and Corporate [email protected]

This article first appeared on GuruFocus. Net Revenue: $57.5 million in Q2 2026, a 17% increase year-over-year and an 11% increase quarter-over-quarter. First Half Net Revenue Growth: Approximately 24% increase compared to the same period a year ago. Gross-to-Net Deductions: Increased to 20.7% for Q2 2026, compared to 15.3% in Q2 2025. Research and Development Expenses: $22 million in Q2 2026, compared to $21.7 million in Q2 2025. Selling, General and Administrative Expenses: $38.9 million in Q2 2026, compared to $38.6 million in Q2 2025. Total Operating Expenses (excluding cost of goods sold): $60.7 million in Q2 2026, compared to $60.3 million in Q2 2025. Cash Position: Approximately $327 million in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2026. 2026 Net Revenue Guidance: Expected to come in at the mid- to high end of the $220 million to $240 million range. 2026 Total Operating Expense Guidance: Expected to remain in the range of $230 million to $240 million. Warning! GuruFocus has detected 4 Warning Signs with GERN. Is GERN fairly valued? Test your thesis with our free DCF calculator. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Geron Corp (NASDAQ:GERN) reported strong Q2 2026 net revenue of $57.5 million, a 17% year-over-year increase and 11% quarter-over-quarter growth, with first-half revenue up 24% year-over-year. The company raised its full-year 2026 RYTELO net revenue guidance to the mid-to-high end of the $220-$240 million range, reflecting solid commercial execution. Total operating expenses decreased by 4% in the first half of 2026 compared to the prior year, while net revenue grew 24%, demonstrating improved financial discipline. Geron Corp (NASDAQ:GERN) expanded its prescribing accounts to approximately 1,575, with an 8% increase in the quarter, and saw 34% of patient starts in the first/second-line setting on a rolling 12-month basis. The company presented positive real-world evidence for RYTELO at EHA, which was consistent with Phase 3 IMerge trial results, reinforcing its safety and efficacy profile in lower-risk MDS. Geron Corp (NASDAQ:GERN) maintains a strong balance sheet with $327 million in cash, providing flexibility to invest in commercial growth and strategic opportunities. The company is proactively engaging with regulatory authorities to ensure the interim analysis of the Phase 3 IMPACT MF trial is adequate for potential registration, with timelines unchanged. Geron Corp (NASDAQ:GERN) is exploring European commercialization strategies, recognizing significant unmet need and potential for thousands of patients, with plans to share details before year-end. Gross-to-net deductions increased to 20.7% in Q2 2026 from 15.3% in Q2 2025, which could pressure future net revenue growth. The company faces uncertainty regarding the impact of the Inflation Reduction Act's Most Favored Nation (MFN) pricing model on European commercialization, potentially limiting pricing flexibility. Geron Corp (NASDAQ:GERN) is evaluating a modification to the event threshold for the interim analysis of the IMPACT MF trial, which could introduce regulatory and timeline risks. The company's reliance on a limited number of high-volume community accounts for growth may create concentration risk, though depth is becoming a focus. Operating expenses remain elevated, with SG&A costs flat year-over-year and R&D expenses increasing due to CMC investments, despite overall cost discipline. The company lacks a reliable metric to track duration of therapy, making it difficult to assess patient persistence and long-term adoption trends. European commercialization plans are still in exploration, with no concrete timeline for launch, and the company must navigate evolving pricing rules and payer dynamics. The IMPACT MF trial's base case timeline extends to the second half of 2028 for final analysis, indicating a long wait for potential upside from the myelofibrosis program. Q: Can you provide more detail on the discussions with the FDA regarding the interim analysis for the Phase 3 IMPACT MF trial, and whether the final overall survival analysis threshold is also being considered for modification? A: CEO Harout Semerjian explained that the company is proactively engaging with regulatory authorities to ensure the interim analysis design is adequate to support registration, given the trial began in the early 2020s and standards of care have evolved. They are evaluating a modification to the event threshold for the interim analysis while remaining blinded to treatment assignment. CMO Joseph Eid clarified that the final analysis, including the overall survival primary endpoint and its timing, remains unchanged. The base case projection for the final OS analysis remains the second half of 2028, with an earlier positive interim outcome representing an upside scenario. Q: Given the strong second quarter results, how should we think about seasonality impacting the rest of the year, and will these efforts be offset by the commercial strategy inflection you've guided to in the back half? A: CFO Michelle Robertson stated that the company manages inventory within a two-to-four-week range and expects gross-to-net deductions to remain in the low-to-mid 20s for the remainder of 2026. She does not anticipate significant spikes or decreases in the back half of the year, and the company expects consistent quarter-over-quarter growth, positioning them to come in at the mid-to-high end of the full-year revenue guidance of $220 million to $240 million. Q: As you grow your prescribing accounts, is the growth coming from increased reordering from existing accounts or primarily from new accounts? Additionally, are you seeing an increase in persistence or time on therapy as you see more first- and second-line patient starts? A: CCO Ahmed Elnawawi noted that growth is coming from both new and existing accounts. As the strategy executes successfully, breadth (new accounts) will play a smaller component in the second half, with depth (reordering from existing accounts) becoming a more focused metric. High-tier community accounts are responding well to messaging and playing a bigger role in the business. Regarding duration of therapy, the company does not have a reliable metric to track persistence, so they cannot confirm an increase or decrease. Q: Regarding the EU commercial strategy, given the Most Favored Nation (MFN) pricing concerns, would this strategy focus on countries without visible net prices? And does the potential path forward include partnerships? A: CEO Harout Semerjian confirmed that the company sees as much opportunity in Europe as in the US, with thousands of eligible patients. They are actively engaging with medical experts and payers, and monitoring the evolving MFN dynamics closely. The strategy could include or exclude partnership conversations, and they expect to share an optimized ex-US strategy, particularly for major countries like Germany and France, before year-end. Q: Can you elaborate on the real-world evidence presented at EHA and how it validates RYTELO's profile in a broader patient population? A: CMO Joseph Eid discussed the first real-world evidence study of RYTELO in low-risk MDS, conducted in collaboration with Moffitt Cancer Center. The retrospective portion showed findings generally consistent with the Phase 3 IMerge trial, reinforcing the safety, efficacy, and tolerability profile in a broader, heavily transfusion-dependent patient population, including those with extensive prior therapies. The data also showed a trend toward optimal management of cytopenias and improved responses when RYTELO was used within the first three lines of therapy. The prospective portion is expected to provide additional insights at a future scientific meeting. Q: What is driving the increase in gross-to-net deductions, and what should we expect for the remainder of 2026? A: CFO Michelle Robertson reported that gross-to-net deductions increased to 20.7% in Q2 2026, up from 15.3% in Q2 2025. For the remainder of 2026, the company continues to expect gross-to-net to be in the low-to-mid 20s, reflecting typical commercial dynamics such as discounts, rebates, and patient assistance programs. Q: Can you provide more color on the demand growth and prescribing account expansion in the second quarter? A: CCO Ahmed Elnawawi reported 5% demand growth for RYTELO compared to Q1 2026 and an 8% increase in prescribing accounts, expanding the footprint to approximately 1,575 accounts since launch. First- and second-line patient starts on a rolling 12-month basis were 34%. The company estimates around 8,000 eligible second-line lower-risk MDS patients in the US, representing a significant opportunity for continued growth. Q: How is the company balancing investment in growth opportunities with financial discipline, and what is the current cash position? A: CFO Michelle Robertson highlighted that first-half 2026 total operating expenses decreased 4% year-over-year while net revenue grew 24%, underscoring operational execution and financial discipline. The company ended Q2 with approximately $327 million in cash, cash equivalents, restricted cash, and marketable securities. They remain well capitalized to fund growth from current operations and deliver on 2026 financial guidance. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Interested in Geron Corporation? Here are five stocks we like better. Geron reported strong second-quarter performance, with revenue rising 17% year over year to $57.5 million and first-half revenue up approximately 24%. The company ended the quarter with $327 million in cash, equivalents, restricted cash and marketable securities. RYTELO demand increased 5% sequentially, while prescribing accounts grew 8% to about 1,575. Geron now expects 2026 RYTELO revenue toward the mid-to-high end of its existing $220 million–$240 million guidance range. Geron continues advancing RYTELO’s real-world evidence and its Phase III IMpactMF myelofibrosis trial, while exploring European commercialization options. The company expects to update investors on its European strategy before the end of 2026. Geron Corporation: FDA Approval Fuels Stock Price Surge Geron (NASDAQ:GERN) reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with lower-risk myelodysplastic syndromes, or MDS. Chief Executive Officer Harout Semerjian said first-half net revenue rose approximately 24% from the same period in 2025, while total operating expenses declined 4%. The company ended the quarter with $327 million in cash, cash equivalents, restricted cash and marketable securities. → SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Geron Stock Doubles After Imetelstat Receives FDA Panel Approval “We delivered another quarter of net revenue growth, expanding RYTELO's reach to more eligible patients,” Semerjian said. “We delivered another quarter of net revenue growth, expanding RYTELO's reach to more eligible patients, strengthened the clinical evidence supporting RYTELO, continued investing in future growth opportunities, all while remaining financially disciplined.” Geron said RYTELO demand increased 5% in the second quarter compared with the first quarter, marking its third consecutive quarter of demand growth. The number of prescribing accounts increased 8% to approximately 1,575 since the product's launch. → 3 Drone Stocks That Should Soar After the Summer Slump Ahmed ElNawawi, Geron’s chief commercial officer, said patient starts in the first- and second-line settings represented 34% on a rolling 12-month basis. The company is prioritizing high-volume community treatment centers, earlier identification of eligible patients, account management and targeted engagement with health-care professionals. Geron estimates that approximately 8,000 patients in the United States may be eligible for RYTELO in the second-line, lower-risk MDS setting. → The Bitcoin Comeback May Already Be Underway—2 ETFs for Exposure During the question-and-answer session, Semerjian said sales growth is coming from both new and existing prescribing accounts. ElNawawi added that the company expects expansion into new accounts, or breadth, to become a smaller contributor during the second half, while greater use within existing accounts, or depth, becomes a more important metric. ElNawawi said Geron does not currently have a reliable metric for measuring duration of therapy and therefore cannot determine whether persistence is increasing or decreasing. Based on first-half performance, Geron expects 2026 RYTELO net product revenue to land at the mid-to-high end of its previously stated $220 million to $240 million guidance range. The company continues to expect total operating expenses of $230 million to $240 million for the year. Chief Financial Officer Michelle Robertson said the company expects consistent quarter-over-quarter revenue growth through the remainder of 2026. Geron manages inventory within a two- to four-week range and does not expect significant inventory-related increases or decreases in the second half, she said. Second-quarter gross-to-net deductions rose to 20.7%, compared with 15.3% in the year-earlier period. Geron continues to expect gross-to-net deductions in the low-to-mid-20% range for the remainder of the year. Research and development expense was $22 million, compared with $21.7 million a year earlier. Selling, general and administrative expense was $38.9 million, compared with $38.6 million in the prior-year quarter. Total operating expenses, excluding cost of goods sold, were $60.7 million, compared with $60.3 million a year earlier. Robertson attributed higher research and development spending to investments in chemistry, manufacturing and controls, or CMC, and said higher marketing expenses affected selling, general and administrative costs. These increases were partially offset by lower personnel costs following the company’s workforce reduction in December 2025. At the European Hematology Association congress, Geron presented retrospective results from an investigator-sponsored real-world study conducted with Moffitt Cancer Center. The two-part retrospective and prospective study is evaluating RYTELO’s safety and clinical efficacy in advanced, heavily transfusion-dependent lower-risk MDS patients, including patients with extensive prior therapies and prior luspatercept failure. Semerjian said the retrospective findings were generally consistent with the Phase III IMerge trial and supported RYTELO’s safety, efficacy and tolerability profile in a broader patient population. The data also indicated a trend toward better management of cytopenias and improved responses when RYTELO was used in the first three lines of therapy. Chief Medical Officer Joseph Eid said the company expects to present insights from the prospective portion of the study at a future scientific meeting. Geron also discussed its Phase III IMpactMF trial of imetelstat in relapsed or refractory myelofibrosis. The company has engaged regulators and outside experts regarding the design of the trial’s interim analysis and is evaluating a modification to the event threshold that would support registration if the data monitoring committee recommends unblinding for positive efficacy. Eid said the potential modification concerns the interim analysis and would not change the final overall-survival analysis, which remains the trial’s primary endpoint. Geron’s base-case expectation remains for the final overall-survival analysis in the second half of 2028, while a positive result at the interim analysis would be an earlier upside scenario. Geron said it is exploring a “gated” commercialization strategy for RYTELO in Europe and other markets while seeking to preserve U.S. pricing integrity. The company expects to provide an update on its European commercialization plans before the end of 2026. Semerjian said Geron sees a patient opportunity in Europe comparable in scale to the U.S. market and is engaging medical experts and payers. He said the company is monitoring evolving most-favored-nation dynamics and expects to assess potential approaches in major markets including Germany and France. Potential strategies could include partnership arrangements, he said. Geron also announced that Chinmaya Rath joined the company as chief business officer. Semerjian said Rath’s appointment supports the company’s effort to identify strategic growth opportunities and build Geron into a leading hematology company. Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company's research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options. The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Geron Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Achieved 17% year-over-year net revenue growth for RYTELO, driven by a refocused commercial strategy and increased penetration in community treatment centers. Demonstrated significant operating leverage with net revenue increasing 24% in the first half of 2026 while total operating expenses decreased by 4%. Shifted commercial focus toward high-volume community accounts, which management identifies as the primary driver for future depth and market penetration. Validated RYTELO's clinical profile through real-world evidence presented at EHA, showing consistency with Phase III IMerge results in advanced, heavily transfusion-dependent patients. Strengthened the leadership team with a new Chief Business Officer to focus on business development and maximizing the value of the current hematology portfolio. Maintained a strong balance sheet with $327 million in cash, providing flexibility for commercial investment and opportunistic innovation. Anticipate full-year 2026 RYTELO net revenue at the mid-to-high end of the $220 million to $240 million guidance range. Evaluating a modification to the event threshold for the IMpactMF interim analysis to ensure the design is adequate for potential registration. Projected timeline for final overall survival analysis in relapsed/refractory myelofibrosis remains set for the second half of 2028. Expect to announce a gated European commercialization strategy before year-end, prioritizing pricing integrity and navigating evolving Most Favored Nation (MFN) dynamics. Guidance for 2026 total operating expenses remains at $230 million to $240 million, reflecting disciplined investment in CMC and commercial acceleration. Operating expenses benefited from lower headcount costs following a strategic workforce reduction implemented in December 2025. Gross-to-net deductions increased to 20.7% in Q2 2026, with expectations to remain in the low-to-mid 20s for the remainder of the year. Management is proactively engaging with regulators to align on interim analysis thresholds for IMpactMF due to changes in standard of care since the trial's inception. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management does not expect significant spikes or decreases in the back half of the year due to seasonality. Inventory levels are being strictly managed within a 2 to 4 week range to ensure consistent quarter-over-quarter growth. Growth is currently coming from both new and existing accounts, but the strategy is shifting to prioritize 'depth' over 'breadth' in the second half of the year. High-tier community accounts are showing strong responsiveness to evidence-based messaging, becoming a larger component of the business. Discussions with the FDA are focused specifically on the interim analysis event threshold rather than changing the primary endpoint or final analysis timing. The goal is to ensure the interim analysis can support registration if the Data Monitoring Committee recommends unblinding for positive efficacy. The company is exploring both direct commercialization and potential partnerships for the European market. A key priority is maintaining U.S. pricing integrity while monitoring evolving international pricing models like the Globe and Guard models.

Precigen, Inc. (PGEN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +350.00%. A quarter ago, it was expected that this company would post a loss of $0.03 per share when it actually produced a loss of $0.02, delivering a surprise of +33.33%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Precigen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $54.98 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 97.62%. This compares to year-ago revenues of $0.86 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Precigen shares have added about 58.1% since the beginning of the year versus the S&P 500's gain of 11%. While Precigen has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Precigen was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is breakeven on $34.64 million in revenues for the coming quarter and -$0.02 on $127.74 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Geron (GERN), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5. This drugmaker is expected to post quarterly loss of $0.01 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Geron's revenues are expected to be $55.01 million, up 12.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Precigen, Inc. (PGEN) : Free Stock Analysis Report Geron Corporation (GERN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Regeneron (REGN) came out with quarterly earnings of $14.29 per share, beating the Zacks Consensus Estimate of $10 per share. This compares to earnings of $12.89 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +42.90%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $8.52 per share when it actually produced earnings of $9.47, delivering a surprise of +11.15%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Regeneron, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $4.29 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 11.74%. This compares to year-ago revenues of $3.68 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Regeneron shares have lost about 9.9% since the beginning of the year versus the S&P 500's gain of 6.9%. While Regeneron has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Regeneron was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $12.58 on $4.1 billion in revenues for the coming quarter and $45.50 on $15.75 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Geron (GERN), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5. This drugmaker is expected to post quarterly loss of $0.01 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Geron's revenues are expected to be $55.01 million, up 12.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Geron Corporation (GERN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Geron (GERN) has put its first quarter 2026 results front and center for investors, highlighting higher RYTELO revenue, a smaller net loss and reaffirmed full year guidance as the core of the latest update. See our latest analysis for Geron. Despite the Q1 beat and reaffirmed guidance, Geron’s recent share price performance has been weak, with a 30 day share price return of 16.1% and a 7 day share price return of 5.2%. The 1 year total shareholder return of 15.9% contrasts with a 3 year total shareholder return of 49.5%, which hints that recent earnings momentum has not fully shifted longer term sentiment. If you are looking beyond Geron in the same broad theme, this is a good moment to scan for other healthcare companies applying AI in medicine with the 35 healthcare AI stocks. With RYTELO revenue rising, losses narrowing and guidance intact, but the stock down 16.1% over 30 days and still loss making, is Geron now trading below its potential, or is the market already pricing in future growth? Geron’s most followed narrative places fair value at $3.40, well above the last close at $1.46, which sets up a wide valuation gap for investors to assess. Read the complete narrative. Curious what kind of revenue curve, margin reset, and future earnings power are baked into that fair value, and how they link back to analysts’ long term assumptions? The full narrative spells out the growth rates, profitability swing and valuation multiple that need to line up for $3.40 to make sense. Result: Fair Value of $3.40 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this narrative still hinges on RYTELO carrying most of the commercial load and on Geron funding its pipeline without equity raises that significantly dilute existing shareholders. Find out about the key risks to this Geron narrative. If this mix of optimism and caution resonates with you, now is a good time to check the numbers yourself and pressure test the bullish case. To see what other investors are focusing on, take a closer look at the 3 key rewards Before you move on, consider building a broader watchlist and letting data driven stock ideas do some of the heavy lifting for you. Target potential mispricings by scanning companies that appear to offer value with the 51 high quality undervalued stocks. Prioritise resilience by checking out companies highlighted in the 72 resilient stocks with low risk scores. Hunt for future standouts by reviewing the screener containing 23 high quality undiscovered gems. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include GERN. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]